Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has maintained its Overweight rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ...

Following poor IL-33 data in late May, the company believes that the recent selloff in Regeneron Pharmaceuticals ... for an extremely undervalued AI stock that also stands to benefit significantly ...

This mixed outcome, combined with unmet high expectations for the drug’s performance, triggered a sharp sell-off ... looking for an AI stock that is more promising than REGN and that has ...

Wall Street analysts issued a fresh round of ratings changes on Friday, including notable downgrades for Airbnb (ABNB), Regeneron (REGN), and Cooper Companies (COO), and upgrades for Unity (U) and ...

Tesla ( TSLA) was the best-performing stock in the S&P 500 as the feud between CEO Elon Musk and President Donald Trump that ...

Ohtuvayre's rapid US launch boosts Verona's growth with Q1 2025 sales up 95%. Read more on VRNA stock's blockbuster potential ...

U.S. equities were mixed at midday, with the market following the progress of the Republican tax cut and spending bill that could be heading to a vote soon.

Crispr Therapeutics AG leverages CASGEVY's rollout, a robust pipeline in cardiovascular, oncology, & partnerships to large ...

Kenvue Inc.'s stock had its worst day in nearly two years on Tuesday, as the maker of Band-Aids, Benadryl and Tylenol said tariffs, persistent inflation and weaker demand for allergy medicine, due to ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying opportunity?

This was the stock's second consecutive day of losses.